I

Integra LifeSciences

Regenerative medicine, surgical devices provider

Vice President of Corporate Financial Planning & Analysis

Full-Time
$225.4k - $316.3k+ Bonus + Commission + Equity
Expert
Bachelor's, Master's, MBA
Princeton, NJ, USA
HybridOn-site presence Tuesday through Thursday is required.
Finance & BankingCorporate Finance & FP&A

About the job

Requirements
  • Demonstrated success leading enterprise planning, forecasting, long-range planning, performance management, and executive reporting across multiple business units, product lines, functions, and/or geographies.
  • Proven experience leading an FP&A or finance transformation, including process redesign, operating-model evolution, technology deployment, change management, and adoption.
  • Strong understanding of accounting and financial statements, with the ability to integrate profit and loss, balance sheet, cash flow, and operational drivers into a coherent forward view.
  • Experience partnering with C-suite leaders and presenting to executive leadership teams and Boards; able to synthesize complex information into a clear point of view and influence decisions without relying solely on formal authority.
  • Track record of building and developing high-performing teams, leading through ambiguity, and balancing strategic transformation with reliable execution of recurring deliverables.
  • A bachelor's degree in finance, accounting, economics, business administration, or a related field is required.
  • At least 15 years of progressive finance experience, including substantial leadership responsibility in FP&A, business finance, strategic finance, or a related discipline within a complex, global organization.
  • Balances division needs with company-wide priorities and optimizes for long-term enterprise value.
  • Moves fluidly between strategic context, operating drivers, and financial detail; forms fact-based perspectives and makes complex information understandable.
  • Creates a compelling transformation vision, sequences change pragmatically, and personally drives adoption, accountability, and sustained results.
  • Communicates with clarity, brevity, and confidence; anticipates questions and tailors insights to the audience.
  • Builds trust across Finance, business, and technology stakeholders; challenges constructively and resolves competing priorities.
  • Sets high standards, develops successors, and creates an environment in which diverse talent can perform and grow.
  • Proficiency in Microsoft Office Suite and statistical analysis software.
  • Familiarity with health, safety, and environmental regulations related to manufacturing.
Responsibilities
  • Serve as enterprise owner of the annual operating plan, periodic forecasting processes, and long-range planning cycle.
  • Direct consolidation of divisional, product portfolio, geographic, and corporate plans into a unified enterprise outlook aligned with strategic objectives, capital allocation priorities, and value creation goals.
  • Establish enterprise planning assumptions, governance processes, calendars, deliverables, review forums, and decision gates to drive accountability, facilitate executive decision-making, and support recommendations to the CFO, Executive Leadership Team, and Board of Directors.
  • Lead monthly and quarterly performance reviews covering revenue, volume, price, mix, gross margin, operating expenses, cash flow, profitability, and other business drivers; distinguish structural trends from timing items, surface risks and opportunities, and drive actions and accountability.
  • Deliver high-impact analyses and Board-ready reporting that translate financial and operational performance into strategic insights for the CFO and Executive Leadership Team.
  • Develop an enterprise narrative highlighting risks, opportunities, and value-creation drivers to enable informed decisions and actionable recommendations.
  • Partner with the CFO, division presidents, and functional leaders on resource allocation, portfolio choices, productivity, investment cases, restructuring, capital deployment, and other enterprise decisions.
  • Create scenario and sensitivity analyses to clarify trade-offs and financial implications.
  • Define and execute the FP&A technology roadmap across enterprise performance management, business intelligence, data visualization, workflow, automation, and advanced analytics.
  • Move the organization from spreadsheet-intensive processes toward governed, scalable, connected planning solutions.
  • Expand the use of driver-based models, rolling forecasts, predictive analytics, and AI-assisted insights where appropriate; establish human review, model transparency, and control standards.
  • Create common definitions, hierarchies, and ownership for management reporting and key performance indicators.
  • Partner with Accounting, IT, and data teams to improve source-system integration, data quality, reconciliation, and traceability from operational drivers to reported financial outcomes.
  • Standardize planning and reporting processes, reduce cycle time and manual effort, improve forecast accuracy, and establish measurable service and performance standards.
  • Champion continuous improvement and scalable ways of working.
  • Serve as a strategic advisor to division and functional FP&A leadership, cultivating trusted relationships that drive enterprise performance.
  • Integrate historical financial results with operational drivers, forward-looking assumptions, and strategic priorities to deliver actionable insights.
  • Provide thoughtful challenge, elevate decision quality, and champion consistency in planning, forecasting, and performance management while balancing enterprise objectives with the dynamics of each business.
  • Lead, develop, and inspire a team of approximately 15–20 direct and indirect professionals.
  • Build team capabilities in business partnering, analytics, technology, executive communication, and strategic thinking; strengthen succession pipelines and foster an inclusive, high-accountability culture.
  • Ensure planning, forecasting, and management reporting processes operate with appropriate controls, documentation, and version discipline.
  • Partner effectively with Controllership, Treasury, Tax, Investor Relations, Internal Audit, and other stakeholders.
  • Perform other related duties as required.
Desired Qualifications
  • Experience in medical technology, life sciences, manufacturing, or another regulated, multi-site industry is strongly preferred.
  • Public-company experience is preferred.
  • An MBA, Master of Accountancy, CPA, or comparable advanced credential is preferred.

About the company

Integra LifeSciences develops medical technologies for tissue repair and regeneration, including tissue-regeneration scaffolds, neurosurgical devices, wound care products, and specialized surgical instruments. Its scaffolds are implanted on wounds to provide a temporary matrix that guides new tissue growth and gradually integrates with the patient's tissue. The company differentiates itself through a diversified, multi-domain portfolio built via acquisitions, spanning regenerative medicine and conventional medical devices. Its goal is to broaden access to regenerative technology and raise standards of care in surgery and tissue repair.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Plainsboro Township, New Jersey

Founded

1989

Get referred to Integra LifeSciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $391.9 million, with organic growth and raised EPS guidance.
  • S&P upgraded Integra to B on October 1, 2026, citing normalization progress.
  • Management targets $200 million operating cash flow in 2026, aided by cost savings.

What critics are saying

  • Cincinnati flooding cuts Q3 revenue $7 million and Q4 revenue $15 million to $20 million.
  • The Cincinnati plant returns only in Q2 2027, extending customer loss and backlog risk.
  • Boston cGMP securities litigation threatens damages, injunctions, and existential brand erosion.

What makes Integra LifeSciences unique

  • Integra spans neurosurgery, wound care, and reconstructive biologics, reducing single-product dependence.
  • Braintree's June 2026 ramp and Q4 2026 SurgiMend relaunch restore proprietary supply control.
  • 2027 Liberties launch and SurgiMend PMA target create new neurosurgery and breast-reconstruction wedges.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Medical Insurance
  • Dental Insurance
  • Vision Insurance
  • Short-Term Disability
  • Long-Term Disability
  • 401(k) Retirement Plan

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

4%

2 year growth

4%
Associated Press
Oct 9th, 2026
Integra prices $450M senior secured notes at 9.5% to refinance credit facilities

Integra LifeSciences Holdings Corporation has priced $450 million in senior secured notes due 2033, carrying a 9.500% interest rate. The medical technology company expects to close the sale on or around 19 October 2026, subject to customary closing conditions. The notes will be general senior secured obligations guaranteed by Integra's wholly-owned domestic subsidiaries that guarantee the company's existing senior secured credit facilities. Integra plans to use proceeds from the offering, combined with borrowings under new credit facilities, to refinance existing credit facilities and cover associated fees and expenses. The offering forms part of a broader refinancing transaction. The notes were offered only to qualified institutional buyers and certain non-US persons, relying on exemptions from Securities Act registration requirements. Integra LifeSciences is a global medical technology company specialising in neurosurgery and tissue reconstruction.

Associated Press
Oct 2nd, 2026
Integra LifeSciences cuts 2026 guidance after Cincinnati flooding disrupts production

Integra LifeSciences has lowered its full-year 2026 financial guidance following flooding at its Cincinnati manufacturing facility in July. The medical technology company now expects annual revenue of $1.634 billion to $1.654 billion, down from previous guidance of $1.654 billion to $1.695 billion. The flooding disrupted production of several products in the company's Specialty Surgical Technologies portfolio. Integra estimates the supply disruption reduced third quarter revenue by approximately $7 million and will impact fourth quarter revenue by $15 million to $20 million. The company expects third quarter revenue of $410 million to $412 million and adjusted earnings per share of $0.55 to $0.59. Full-year adjusted earnings per share guidance has been revised to $2.30 to $2.40, down from $2.40 to $2.50. Integra maintains property and business interruption insurance and expects recoveries to mitigate a substantial portion of the earnings impact. The facility is expected to return to full manufacturing operations during the second quarter of 2027.

MarketScreener
Oct 2nd, 2026
Integra LifeSciences Launches $600 Million Senior Secured Term Loan B

Integra LifeSciences said Friday that it has launched a $600 million seven-year senior secured term loan B as part of a broader refinancing transaction. The medical technology company said it...

Yahoo Finance
May 29th, 2026
Integra LifeSciences shares jump 6% after Citigroup upgrades rating and raises price target to $16

Integra LifeSciences shares rose 6.1% after Citigroup upgraded its rating from Sell to Neutral and raised its price target to $16 from $11. Analyst Joanne Wuensch's upgrade reflects reduced downside risk, though not yet a bullish outlook. The upgrade follows strong first-quarter 2026 results reported 22 days earlier, when the stock gained 5.3%. Integra's revenue grew 2.4% year-on-year to $391.9 million, beating estimates, whilst adjusted earnings per share of $0.54 exceeded consensus by 32.8%. The company raised its full-year earnings guidance and appointed Stuart Essig as CEO. Integra shares are up 36.7% year-to-date and recently hit a 52-week high of $16.42, though five-year returns remain significantly negative.

Yahoo Finance
May 17th, 2026
Integra LifeSciences targets $200M operating cash flow as SurgiMend relaunch nears Q4

Integra LifeSciences reported first-quarter revenue and earnings per share above guidance, citing progress in its operational transformation efforts. Chief Financial Officer Lea Knight said internal indicators show fewer supply disruptions, better yields and improved cash flow. The company is maintaining its focus on neurosurgery, tissue reconstruction and ENT markets following a leadership change that saw Stuart return as chairman and CEO. Integra is preparing to relaunch SurgiMend in the fourth quarter after operationalising its Braintree manufacturing facility in June and rebuilding inventory in the third quarter. Management expects $25 million to $30 million in cost savings and is targeting approximately $200 million in operating cash flow and $140 million in free cash flow this year. The company also reported reduced tariff pressure, with full-year impacts now expected at $0.10 per share versus a prior estimate of $0.32.